Efficacy in adults with tardive dyskinesia
Only INGREZZA offers tardive dyskinesia (TD) control made simple in just 6 weeks,
with results as early as 2 weeks1,2
LS mean change from baseline in AIMS dyskinesia total score through 6 weeks (ITT population)1-3
* | Based on modeling and simulation. The LS mean is adjusted for baseline AIMS score and disease category and is shown for consistency with 40 mg and 80 mg observed values from the KINECT 3 study. |
3.1-POINTGREATER REDUCTION
|
|
a | P≤0.001 dose that was statistically significantly different from placebo to control for multiple comparisons. |
Mean baseline AIMS score (SD): placebo 9.9 (4.3), 40 mg 9.8 (4.1), 80 mg 10.4 (3.6). |
|
AIMS, Abnormal Involuntary Movement Scale; BL, baseline; ITT, intent-to-treat; LS mean, least squares mean; SD, standard deviation; SEM, standard error of mean. |
STUDY DESIGN
3.1-POINT
GREATER REDUCTION
FOR INGREZZA 80 MG
VS PLACEBO AT WEEK 6
(EFFECT SIZE=0.9)1,2
INGREZZA 80 mg reduced uncontrolled movements in 7 of 10 patients at 6 weeks1,3,†
Percent of patients with specified magnitude of AIMS total score improvement at the end of Week 61,3,†

† | Post hoc analysis included patients who had a baseline and a Week 6 AIMS total score. Reduction in uncontrolled movements as assessed by ≥1-point decrease in AIMS total score (n=70). |
Mean baseline AIMS score (SD): placebo 9.9 (4.3), 40 mg 9.8 (4.1), 80 mg 10.4 (3.6). |
AIMS, Abnormal Involuntary Movement Scale; SD, standard deviation. |
STUDY DESIGN
Continued TD improvements were sustained with simple one-capsule, once-daily dosing1,4
Extension study of INGREZZA 40 mg and INGREZZA 80 mg (ITT population)1,3,4

AIMS, Abnormal Involuntary Movement Scale; BL, baseline; DBPC, double-blind placebo-controlled; DFWO, drug-free washout; ITT, intent-to-treat. |
STUDY DESIGN
~39% REDUCTION
IN TD SEVERITY WITH
INGREZZA 80 MG
AT 48 WEEKS1,4,‡
‡ | In a post hoc analysis that included patients randomized to INGREZZA 80 mg at baseline and those who were re-randomized to INGREZZA 80 mg at Week 6 (n=65). |
SIMPLE FROM
THE START
The only VMAT2 inhibitor that offers an effective starting dosage you can adjust based on response and tolerability1
EXPLORE DOSINGSEE REAL-WORLD RESULTS
WITH INGREZZA
View videos of real-world patients with TD treated with INGREZZA
REVIEW CASES
INGREZZA CLINICAL
SAFETY DATA
INGREZZA was studied across a broad range of TD patients
REVIEW SAFETY
See more results for INGREZZA
See why long-term treatment with INGREZZA 40 mg may be appropriate for some patients.a Review results of the KINECT 4 study—a phase 3, long-term, open-label study designed to be reflective of TD treatment in clinical practice.5
aRecommended dosage is 80 mg once daily, but patients may be maintained or |
Watch expert perspective videos on INGREZZA
Featuring Amy LaCouture, RN, BSN, PMHNP-BC
Why I choose INGREZZA for my adult patients with tardive dyskinesia (TD)


Case study: John, a patient with schizophrenia and tardive dyskinesia (TD)

These videos were sponsored and developed by Neurocrine Biosciences.
The speaker is a paid consultant of Neurocrine Biosciences.
REFERENCES:
- INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.
- Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-484.
- Data on file. Neurocrine Biosciences, Inc.
- Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry. 2017;78(9):1344-1350.
- Marder SR, Singer C, Lindenmayer JP, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39(6):620-627.